CRISPR-Cas9 Mouse monoclonal Antibody IgM
Fig1: Western blot analysis of CRISPR-Cas9 on 293T cell lysates using anti-CRISPR-Cas9 antibody at 1/5000 dilution. Lane 1: CRISPR-Cas9 transfected 293 cells lysate Lane 2: Non-transfected 293 cells lysate
Fig2: Immunofluorescence staining CRISPR-Cas9 in CRISPR-Cas9 transfected 293T cells (green). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityMouse
Application SummaryWB, ICC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
BackgroundThe Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Type II system is currently the most commonly used RNA-Guided Endonuclease technology for genome engineering. There are two distinct components to this system: (1) a guide RNA and (2) an endonuclease, in this case the CRISPR associated (Cas) nuclease, Cas9. The gRNA/Cas9 complex is recruited to the target sequence by the base-pairing between the gRNA sequence and the complement to the target sequence in the genomic DNA. For successful binding of Cas9, the genomic target sequence must also contain the correct Protospacer Adjacent Motiff (PAM) sequence immediately following the target sequence.(EM50804)